Dr. David Nathanson is an Assistant Professor of Molecular and Medical Pharmacology in the David Geffen School of Medicine at UCLA. He received his B.S. in 2002 from Willamette University, and his Ph.D. from UCLA under Dr. Paul Mischel in 2011. His graduate studies with Dr. Mischel focused on interrogating the mechanisms in which glioblastomas acquire resistance to targeted therapy. From his work, he discovered a novel “hide and seek” drug resistance mechanism, whereby glioblastoma cells evade targeted drugs by eliminating the targeted genetic mutation (Nathanson et. al, Science, 2014). Dr. Nathanson conducted his post-doctoral work with Drs. Caius Radu and Johannes Czernin, which led to the development of a new therapy to target DNA metabolism in cancer (Nathanson et. al, JEM, 2014). Dr. Nathanson’s current laboratory focuses on identifying the key molecular and functional processes driving glioblastoma with the goal of developing new therapeutic strategies to treat this deadly disease.
Dr. Nathanson is a member of the Jonsson Comprehensive Cancer Center, the Ahmanson Translational Imaging Division, and the Broad Stem Cell Institute at UCLA. He is a former Scholar in Oncologic Molecular Imaging (SOMI) Fellow, NIH T32 awardee, and recipient of the Johnny Mercer Foundation Research Award.
site design + code by ONE LONG HOUSE